News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,088 Results
Type
Article (1032)
Company Profile (4)
Press Release (3052)
Section
Business (1270)
Career Advice (55)
Deals (171)
Drug Delivery (5)
Drug Development (1163)
Employer Resources (11)
FDA (209)
Job Trends (455)
News (2559)
Policy (391)
Tag
Academia (28)
Allergies (3)
Alliances (276)
Alzheimer's disease (6)
Antibody-drug conjugate (ADC) (2)
Approvals (206)
Best Places to Work (389)
Biosimilars (8)
Biotechnology (3)
Breast cancer (2)
Cancer (20)
Career advice (44)
Cell therapy (9)
Clinical research (837)
Collaboration (6)
Complete response letters (3)
COVID-19 (185)
CRISPR (4)
C-suite (2)
Data (27)
Denatured (3)
Diagnostics (30)
Diversity (3)
Diversity, equity & inclusion (3)
Drug pricing (2)
Earnings (553)
Employer branding (7)
Employer resources (10)
Events (572)
FDA (219)
Featured Employer (2)
Funding (9)
Gene editing (7)
Gene therapy (13)
GLP-1 (27)
Government (114)
Healthcare (123)
Immunology and inflammation (6)
Infectious disease (185)
Interviews (11)
IPO (105)
Job creations (86)
Job search strategy (44)
Layoffs (16)
Legal (50)
Lung cancer (2)
Lymphoma (3)
Management (2)
Manufacturing (2)
Medical device (20)
Medtech (20)
Mergers & acquisitions (68)
Metabolic disorders (15)
Neuroscience (8)
NextGen: Class of 2025 (58)
Non-profit (15)
Northern California (20)
Now hiring (13)
Obesity (14)
Opinion (4)
Patents (3)
People (366)
Phase I (261)
Phase II (330)
Phase III (476)
Pipeline (18)
Podcasts (5)
Postmarket research (19)
Preclinical (71)
Rare diseases (5)
Real estate (32)
Recruiting (3)
Regulatory (286)
Research institute (17)
Resumes & cover letters (6)
Series A (5)
Series B (2)
Southern California (2)
Startups (13)
United States (151)
Vaccines (19)
Venture capitalists (3)
Weight loss (12)
Women's health (2)
Date
Last 7 days (8)
Last 30 days (30)
Last 365 days (391)
2025 (28)
2024 (387)
2023 (354)
2022 (557)
2021 (555)
2020 (535)
2019 (333)
2018 (237)
2017 (237)
2016 (167)
2015 (154)
2014 (105)
2013 (108)
2012 (81)
2011 (59)
2010 (45)
Location
Africa (23)
Asia (160)
Australia (58)
California (31)
Canada (2)
Connecticut (2)
Europe (785)
Illinois (2)
Massachusetts (29)
New Hampshire (2)
New York (80)
North Carolina (4)
Northern California (20)
Pennsylvania (4)
South America (23)
Southern California (2)
4,088 Results for "Regeneron".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow conversion of patients to the high-dose formulation.
January 14, 2025
·
2 min read
·
Tristan Manalac
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
·
2 min read
·
Tristan Manalac
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Earnings
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously optimistic about the company’s promising cancer, immunology and genetic medicines pipeline.
November 1, 2024
·
2 min read
·
Tristan Manalac
Legal
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
September 24, 2024
·
2 min read
·
Tristan Manalac
Lymphoma
Regeneron Scores EU Lymphoma Approval for Bispecific Antibody Ordspono
With the FDA’s rejection of Ordspono in March, Monday’s green light from the European Commission marks the first approval worldwide and the first regulatory victory for Regeneron’s bispecific antibody platform.
August 27, 2024
·
2 min read
·
Tristan Manalac
Approvals
FDA Denies Approval of Regeneron’s Linvoseltamab for Multiple Myeloma, Cites Third-Party Issues
The regulator’s Complete Response Letter flagged problems at a third-party fill/finish site, which Regeneron says it has already addressed. The manufacturing facility is currently awaiting reinspection.
August 21, 2024
·
2 min read
·
Tristan Manalac
Cancer
BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
BioNTech and Regeneron will face off against Merck and Moderna, which are advancing their investigational cancer vaccine mRNA-4157/V940 in combination with Keytruda, in advanced melanoma.
July 30, 2024
·
2 min read
·
Tristan Manalac
Legal
Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar
In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.
August 29, 2024
·
2 min read
·
Tristan Manalac
FDA
FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea
The regulator on Monday approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.
May 21, 2024
·
2 min read
·
Tristan Manalac
1 of 409
Next
